Product Description
RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway. (Sourced from: https://www.revmed.com/pipeline/rmc-4630)
Mechanisms of Action: SHP-2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Revolution Medicines
Company Location: REDWOOD CITY CA 94063
Company CEO: Mark A. Goldsmith
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, France, Germany, Italy, Korea, Spain, Taiwan, United Kingdom, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Bladder Cancer|Bronchial Cancer|Bronchogenic Carcinoma|Cervical Cancer|Colorectal Cancer|Esophageal Cancer|Esophageal Diseases|Gastrointestinal Cancer|Intestinal Diseases|Non-Small-Cell Lung Cancer|Ovarian Cancer|Ovarian Diseases|Pancreatic Cancer|Rectal Diseases|Respiratory Tract Cancer|Skin Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma|Thoracic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-003254-23 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2024-06-29 |
|
| RMC-4630-03 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2023-09-30 |
57% |
| RMC-4630-02 | P2 |
Completed |
Small Cell Lung Cancer|Bronchogenic Carcinoma|Thoracic Cancer|Colorectal Cancer|Gastrointestinal Cancer|Bladder Cancer|Ovarian Diseases|Esophageal Cancer|Pancreatic Cancer|Skin Cancer|Bronchial Cancer|Cervical Cancer|Rectal Diseases|Non-Small-Cell Lung Cancer|Esophageal Diseases|Ovarian Cancer|Intestinal Diseases|Respiratory Tract Cancer|Squamous Cell Carcinoma |
2022-02-08 |